Skip to main content

Pancreatic Cancer Clinical Trials

Review the pancreatic cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 126-150 of 273

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Neratinib and Divalproex Sodium in Treating Patients with Advanced Solid Tumors or RAS-Mutated Cancers
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Genetically Engineered Tumor Infiltrating Lymphocytes (KSQ-004EX) for the Treatment of Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Single Protein Encapsulated Doxorubicin for the Treatment of Advanced, Refractory or Relapsed Solid Tumor Malignancies
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Tivozanib and Atezolizumab for the Treatment of Advanced, Unresectable, or Metastatic Immunologically Cold Tumor Types
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Status: Active
Location: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
A Modified Conditionally Replicative Adenovirus Vector (RGDCRAdCOX2F) for the Treatment of Pancreatic Cancer
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Bosentan with Nab-Paclitaxel and Gemcitabine for the Treatment of Unresectable Pancreatic Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
9-ING-41 and Retifanlimab with FOLFIRINOX for the Treatment of Advanced Recurrent or Metastatic Pancreatic Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Fostamatinib in Combination with Gemcitabine and Nab-paclitaxel before and after Surgery for the Treatment of Resectable Pancreatic Cancer
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
Status: Active
Location: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas
Gallium Ga 68-DOTA-5G and Lutetium Lu 177-DOTA-ABM-5G in Diagnosing and Treating Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Ulixertinib and Palbociclib in Treating Patients with Advanced or Refractory Solid Tumors or Metastatic Pancreatic Cancer or Metastatic Melanoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Intra-Tumoral Mitazalimab with Irreversible Electroporation for the Treatment of Locally Advanced Pancreas Cancer
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York